[go: up one dir, main page]

MA38010B1 - Dérivés d'éthynyl utilisés en tant que modulateurs de l'activité des récepteurs mglur5 - Google Patents

Dérivés d'éthynyl utilisés en tant que modulateurs de l'activité des récepteurs mglur5

Info

Publication number
MA38010B1
MA38010B1 MA38010A MA38010A MA38010B1 MA 38010 B1 MA38010 B1 MA 38010B1 MA 38010 A MA38010 A MA 38010A MA 38010 A MA38010 A MA 38010A MA 38010 B1 MA38010 B1 MA 38010B1
Authority
MA
Morocco
Prior art keywords
modulators
receptor activity
derivatives used
mglur5 receptor
ethynyl derivatives
Prior art date
Application number
MA38010A
Other languages
English (en)
Other versions
MA38010A1 (fr
Inventor
Heinz Stadler
Eric Vieira
Georg Jaeschke
Lothar Lindemann
Antonio Ricci
Daniel Rueher
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA38010A1 publication Critical patent/MA38010A1/fr
Publication of MA38010B1 publication Critical patent/MA38010B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des dérivés d'éthynyl de formule (i), dans laquelle y représente n ou ch, r
MA38010A 2012-10-18 2015-04-17 Dérivés d'éthynyl utilisés en tant que modulateurs de l'activité des récepteurs mglur5 MA38010B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12188943 2012-10-18
PCT/EP2013/071476 WO2014060384A1 (fr) 2012-10-18 2013-10-15 Dérivés d'éthynyl utilisés en tant que modulateurs de l'activité des récepteurs mglur5

Publications (2)

Publication Number Publication Date
MA38010A1 MA38010A1 (fr) 2016-01-29
MA38010B1 true MA38010B1 (fr) 2016-10-31

Family

ID=47049068

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38010A MA38010B1 (fr) 2012-10-18 2015-04-17 Dérivés d'éthynyl utilisés en tant que modulateurs de l'activité des récepteurs mglur5

Country Status (25)

Country Link
US (1) US9359301B2 (fr)
EP (1) EP2909178B1 (fr)
JP (1) JP6263542B2 (fr)
KR (1) KR20150070102A (fr)
CN (1) CN104603110B (fr)
AR (1) AR093029A1 (fr)
AU (1) AU2013331782B2 (fr)
BR (1) BR112015002320A2 (fr)
CA (1) CA2879489A1 (fr)
CL (1) CL2015000890A1 (fr)
CR (1) CR20150158A (fr)
EA (1) EA026941B1 (fr)
ES (1) ES2599507T3 (fr)
IL (1) IL237217A (fr)
MA (1) MA38010B1 (fr)
MX (1) MX2015002823A (fr)
MY (1) MY171517A (fr)
NZ (1) NZ703537A (fr)
PE (1) PE20150733A1 (fr)
PH (1) PH12015500346A1 (fr)
SG (1) SG11201500729SA (fr)
TW (1) TWI504593B (fr)
UA (1) UA114008C2 (fr)
WO (1) WO2014060384A1 (fr)
ZA (1) ZA201500343B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2712633C1 (ru) 2015-06-03 2020-01-30 Ф. Хоффманн-Ля Рош Аг Этинильные производные
MX374409B (es) 2015-07-15 2025-03-04 Hoffmann La Roche Derivados de etinilo como moduladores del receptor de glutamato metabotrópico.
MX2018011765A (es) 2016-03-30 2019-05-20 Sinntaxis AB Moduladores alostéricos negativos del receptor 5 metabotrópico de glutamato (mglur5) para su uso en el tratamiento de daños cerebrales maduros.
PL3484889T3 (pl) 2016-07-18 2020-12-28 F. Hoffmann-La Roche Ag Pochodne etynylu

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US7531529B2 (en) * 2003-06-05 2009-05-12 Roche Palo Alto Llc Imidazole derivatives
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US8853392B2 (en) * 2007-06-03 2014-10-07 Vanderbilt University Benzamide mGluR5 positive allosteric modulators and methods of making and using same
US20100273772A1 (en) * 2009-04-23 2010-10-28 Wyeth Llc Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5)
US8389536B2 (en) * 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
US8772300B2 (en) * 2011-04-19 2014-07-08 Hoffmann-La Roche Inc. Phenyl or pyridinyl-ethynyl derivatives
US8957213B2 (en) * 2011-04-26 2015-02-17 Hoffman-La Roche Inc. Ethynyl compounds
WO2013049255A1 (fr) * 2011-09-26 2013-04-04 Vanderbilt University Analogues de 5-(prop-1-yn-1-yl)picolinamide substitué comme modulateurs allostériques des récepteurs de mglur5
UA110995C2 (uk) * 2011-10-07 2016-03-10 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як модулятори метаботропного глутаматного рецептора
UA110862C2 (uk) * 2011-10-07 2016-02-25 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5
EP2875000B1 (fr) * 2012-07-17 2016-09-21 F. Hoffmann-La Roche AG Dérivés d'aryléthynyle
UA113223C2 (xx) * 2012-08-13 2016-12-26 Арилетинілпіримідини
AU2013329739B2 (en) * 2012-09-27 2017-04-20 F. Hoffmann-La Roche Ag Arylethynyl derivatives
WO2014060394A1 (fr) * 2012-10-18 2014-04-24 F. Hoffmann-La Roche Ag Dérivés d'éthynyle comme modulateurs de l'activité du récepteur mglur5
NZ705144A (en) * 2012-10-18 2018-09-28 Hoffmann La Roche Ethynyl derivatives as modulators of mglur5 receptor activity

Also Published As

Publication number Publication date
ZA201500343B (en) 2016-01-27
ES2599507T3 (es) 2017-02-02
IL237217A (en) 2016-11-30
NZ703537A (en) 2018-06-29
MX2015002823A (es) 2015-05-15
PH12015500346B1 (en) 2015-04-20
EA026941B1 (ru) 2017-06-30
WO2014060384A1 (fr) 2014-04-24
SG11201500729SA (en) 2015-06-29
JP2015534961A (ja) 2015-12-07
CN104603110A (zh) 2015-05-06
IL237217A0 (en) 2015-04-30
TW201420575A (zh) 2014-06-01
MA38010A1 (fr) 2016-01-29
US9359301B2 (en) 2016-06-07
TWI504593B (zh) 2015-10-21
CA2879489A1 (fr) 2014-04-24
CR20150158A (es) 2015-04-30
AU2013331782A1 (en) 2015-01-29
BR112015002320A2 (pt) 2017-07-04
CL2015000890A1 (es) 2015-08-07
PH12015500346A1 (en) 2015-04-20
PE20150733A1 (es) 2015-05-17
UA114008C2 (xx) 2017-04-10
EP2909178B1 (fr) 2016-10-05
EA201590676A1 (ru) 2015-08-31
HK1206715A1 (zh) 2016-01-15
AR093029A1 (es) 2015-05-13
AU2013331782B2 (en) 2017-03-09
CN104603110B (zh) 2016-08-31
MY171517A (en) 2019-10-16
EP2909178A1 (fr) 2015-08-26
KR20150070102A (ko) 2015-06-24
US20150225345A1 (en) 2015-08-13
JP6263542B2 (ja) 2018-01-17

Similar Documents

Publication Publication Date Title
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA37519B1 (fr) Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
MA35926B1 (fr) Pyrrolidine-2-carboxamides substitués
MA34644B1 (fr) Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2
MA35819B1 (fr) Composés hétéroaryl pyridones et aza-pyridones en tant qu'inhibiteurs de l'activité btk
MA35089B1 (fr) Inhibiteurs de la production de leucotrienes de type benzodioxane
MA35086B1 (fr) Compose de triazolopyridine
MA35357B1 (fr) Composes de type anilines
MA37959A2 (fr) Dérivés de 5-phénoxy-3h-pyrimidin-4-one et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih
MA35664B1 (fr) Nouveaux dérivés bicycliques de la dihydroisoquinoline-1-one
MA35049B1 (fr) Triazolopyridines
MA34078B1 (fr) Derives d'arylethynyle
MA38192B1 (fr) Dérivés d'indole carboxamide utilisés en tant qu'antagonistes du récepteur p2x7
MA38645A1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
MA39189A1 (fr) Dérivés de 1h-indazole et de 1h-indole antibactériens
MA38112B1 (fr) Dérivés d'imidazopyridazine en tant que modulateurs d'un récepteur gabaa
EA201170997A1 (ru) Производные индола в качестве противораковых агентов
BR112015010791A2 (pt) moduladores de gpr40 de di-hidropirazol
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
MA34578B1 (fr) Composés de tétrahydrofuranyl disubstitués en tant qu'antagonistes du récepteur de la bradykinine b1
MA38010B1 (fr) Dérivés d'éthynyl utilisés en tant que modulateurs de l'activité des récepteurs mglur5
MA35742B1 (fr) Dérivés de n- (4 -quinolinylmethyl) sulfonamide et leur utilisation en tant qu'antihelminthiques
MA38410B1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MA39305A3 (fr) Dérivés d'éthynyle
MA37896A1 (fr) Azahétérocycles utilisés comme inhibiteurs de bir2 et/ou bir3